論文

英文

• Shiba N, Yoshida K, Hara Y, Yamato G, Shiraishi Y, Matsuo H, Okuno Y, Chiba K, Tanaka H, Kaburagi T, Takeuchi M, Ohki K, Sanada M, Okubo J, Tomizawa D, Taki T, Shimada A, Sotomatsu M, Horibe K, Taga T, Adachi S, Tawa A, Miyano S, Ogawa S, Hayashi Y.　 Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Adv. 2019 Oct 22;3(20):3157-3169. doi: 10.1182/bloodadvances.2019000404.
• Hara Y, Shiba N, Yamato G, Ohki K, Tabuchi K, Sotomatsu M, Tomizawa D, Kinoshita A, Arakawa H, Saito AM, Kiyokawa N, Tawa A, Horibe K, Taga T, Adachi S, Taki T, Hayashi Y.　 Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup.　Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16203. [Epub ahead of print]
• Terui K, Toki T, Taga T, Iwamoto S, Miyamura T, Hasegawa D, Moritake H, Hama A, Nakashima K, Kanezaki R, Kudo K, Saito AM, Horibe K, Adachi S, Tomizawa D, Ito E. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.　Genes Chromosomes Cancer. 2019 Oct 13. doi: 10.1002/gcc.22816. [Epub ahead of print]
• Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C, Papaemmanuil E, Metzner M, Kennedy A, Amstislavskiy V, Risch T, Bhayadia R, Samulowski D, Hernandez DC, Stoilova B, Iotchkova V, Oppermann U, Scheer C, Yoshida K, Schwarzer A, Taub JW, Crispino JD, Weiss MJ, Hayashi Y, Taga T, Ito E, Ogawa S, Reinhardt D, Yaspo ML, Campbell PJ, Roberts I, Constantinescu SN, Vyas P, Heckl D, Klusmann JH. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.　Cancer Cell. 2019;36(2):123-138.e10. doi: 10.1016/j.ccell.2019.06.007.
• Nakashima K, Hasegawa D, Tomizawa D, Miyamura T, Hama A, Iwamoto S, Terui K, Adachi S, Taga T. Characteristics and outcomes of children with acute myeloid leukemia and Down syndrome who are ineligible for clinical trials due to severe comorbidities.　Pediatr Blood Cancer. 2019 Nov;66(11):e27942. doi: 10.1002/pbc.27942. Epub 2019 Aug 18
• Hyakuna N, Hashii Y, Ishida H, Umeda K, Takahashi Y, Nagasawa M, Yabe H, Nakazawa Y, Koh K, Goto H, Fujisaki H, Matsumoto K, Kakuda H, Yano M, Tawa A, Tomizawa D, Taga T, Adachi S, Kato K. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial.　Pediatr Blood Cancer. 2019 Oct;66(10): e27875. doi: 10.1002/pbc.27875. Epub 2019 Jul 16
• Sakamoto K, Shiba N, Deguchi T, Kiyokawa N, Hashii Y, Moriya-Saito A, Tomizawa D, Taga T, Adachi S, Horibe K, Imamura T.　Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. Br J Haematol. 2019 Nov;187(3):372-376. doi: 10.1111/bjh.16080. [Epub ahead of print]
• Makimoto A, Mugishima H, Taga T, Ishida Y, Nagatoshi Y, Ida K, Kumagai M, Kimura T, Ohashi Y, Kaneko M. Registration-directed phase 1/2 trial of irinotecan for pediatric solid tumors.　Pediatr Int. 2019 May;61(5):453-458. doi: 10.1111/ped.13826. Epub 2019 May 14
• Miyamura T, Moritake H, Nakayama H, Tanaka S, Tomizawa D, Shiba N, Saito AM, Tawa A, Shimada A, Iwamoto S, Hayashi Y, Koike T, Horibe K, Manabe A, Mizutani S, Taga T, Adachi S.　Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.　Br J Haematol. 2019 Apr;185(2):284-288. doi: 10.1111/bjh.15799. Epub 2019 Feb 19.
• Okamoto Y, Kudo K, Tabuchi K, Tomizawa D, Taga T, Goto H, Yabe H, Nakazawa Y, Koh K, Ikegame K, Yoshida N, Uchida N, Watanabe K, Koga Y, Inoue M, Kato K, Atsuta Y, Ishida H.　Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia.　Bone Marrow Transplant. 2019 Sep;54(9):1489-1498. doi: 10.1038/s41409-019-0461-0. Epub 2019 Feb 4.
• Hara Y, Shiba N, Yamato G, Ohki K, Tabuchi K, Sotomatsu M, Tomizawa D, Kinoshita A, Arakawa H, Saito AM, Kiyokawa N, Tawa A, Horibe K, Taga T, Adachi S, Taki T, Hayashi Y.
• Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. Br J Haematol. 2020 Feb;188(4):528-539. doi: 10.1111/bjh.16203. Epub 2019 Oct 14.PMID: 31612466
• Terui K, Toki T, Taga T, Iwamoto S, Miyamura T, Hasegawa D, Moritake H, Hama A, Nakashima K, Kanezaki R, Kudo K, Saito AM, Horibe K, Adachi S, Tomizawa D, Ito E. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing. Genes Chromosomes Cancer. 2020 Mar;59(3):160-167. doi: 10.1002/gcc.22816. Epub 2019 Oct 21.PMID: 31606922
• Yamamoto S, Tomizawa D, Kudo K, Hasegawa D, Taga T, Yanada M, Kondo T, Nakazawa Y, Eto T, Inoue M, Kato K, Atsuta Y, Ishida H. Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan. Pediatr Blood Cancer. 2020 May;67(5):e28181. doi: 10.1002/pbc.28181. Epub 2020 Jan 21. PMID: 31965692
• Aoki T, Takahashi H, Tanaka S, Shiba N, Hasegawa D, Iwamoto S, Terui K, Moritake H, Nakayama H, Shimada A, Koh K, Goto H, Kosaka Y, Saito AM, Horibe K, Kinoshita A, Tawa A, Taga T, Adachi S, Tomizawa D. Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. Br J Haematol. 2020 Apr. 193(1):176-180. doi: 10.1111/bjh.16656. Online ahead of print. PMID: 32337716
• Saito Y, Sawa D, Kinoshita M, Yamada A, Kamimura S, Suekane A, Ogoh H, Matsuo H, Adachi S, Taga T, Tomizawa D, Osato M, Soga T, Morishita K, Moritake H.　EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.　Haematologica.2020 Aug;105(8):2118-2129.doi: 10.3324/haematol.2019.225953. Epub 2019 Oct 24.PMID: 31649131
• Matsuo H, Yoshida K, Nakatani K, Harata Y, Higashitani M, Ito Y, Kamikubo Y, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Okada A, Nannya Y, Takeda J, Ueno H, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Miyano S, Meggendorfer M, Haferlach C, Ogawa S, Adachi S. Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. Blood Adv. 2020 Oct 13;4(19):4623-4631. doi: 10.1182/bloodadvances.2020002457.PMID: 32991719
• Hasegawa D, Tawa A, Tomizawa D, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Goto H, Kosaka Y, Miyachi H, Horibe K, Nakahata T, Adachi S.　Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).Pediatr Blood Cancer. 2020 Dec;67(12): e28692. doi: 10.1002/pbc.28692. Epub 2020 Sep 4.　PMID: 32886449
• Moritake H, Tanaka S, Miyamura T, Nakayama H, Shiba N, Shimada A, Terui K, Yuza Y, Koh K, Goto H, Kakuda H, Saito A, Hasegawa D, Iwamoto S, Taga T, Adachi S, Tomizawa D,The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study. Pediatr Blood Cancer. 2021 Jan;68(1):e28736. doi: 10.1002/pbc.28736. Epub 2020 Sep 29.PMID: 32991072
• Matsuo H, Wakita T, Hiramatsu H, Ohmori K, Kodama K, Nakatani K, Kamikubo Y, Iwamoto S, Kondo T, Takaori-Kondo A, Takita J, Tomizawa D, Taga T, Adachi S. Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression. Br J Haematol. 2021 Jan;192(1):e7-e11. doi: 10.1111/bjh.17122. Epub 2020 Oct 23.PMID: 33095915
• Taga T, Tanaka S, Hasegawa D, Terui K, Toki T, Iwamoto S, Hiramatsu H, Miyamura T, Hashii Y, Moritake H, Nakayama H, Takahashi H, Shimada A, Taki T, Ito E, Hama A, Ito M, Koh K, Hasegawa D, Saito AM, Adachi S, Tomizawa D. Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia. 2021 Sep;35(9):2508-2516. doi: 10.1038/s41375-021-01157-w. Epub 2021 Feb 15.PMID: 33589754
• Kamitori T, Umeda K, Akazawa R, Iwai A, Obu S, Isobe K, Saida S, Kato I, Hiramatsu H, Taga T, Adachi S, Takita J. Inotuzumab ozogamicin following allogeneic hematopoietic stem cell transplantation successfully rescued relapse of CD19-negative acute lymphoblastic leukemia after CAR-T cell therapy. Pediatr Blood Cancer. 2021 May;68(5):e28980. doi: 10.1002/pbc.28980. Online ahead of print. PMID: 33619887
• Miyahara H, Natsumeda M, Kanemura Y, Yamasaki K, Riku Y, Akagi A, Oohashi W, Shofuda T, Yoshioka E, Sato Y, Taga T, Naruke Y, Ando R, Hasegawa D, Yoshida M, Sakaida T, Okada N, Watanabe H, Ozeki M, Arakawa Y, Yoshimura J, Fujii Y, Suenobu S, Ihara K, Hara J, Kakita A, Yoshida M, Iwasaki Y. Topoisomerase IIβ immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group. Brain Tumor Pathol. 2021 Apr;38(2):109-121. doi: 10.1007/s10014-021-00396-0. Epub 2021 Mar 11.PMID: 33704596
• Sakaguchi H, Miyamura T, Tomizawa D, Taga T, Ishida H, Okamoto Y, Koh K, Yokosuka T, Yoshida N, Sato M, Noguchi M, Okada K, Hori T, Takeuchi M, Kosaka Y, Inoue M, Hashii Y, Atsuta Y. Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study. Bone Marrow Transplant. 2021 Aug;56(8):1859-1865. doi: 10.1038/s41409-021-01250-9. Epub 2021 Mar 10.　PMID: 33692532
• Yamato G, Deguchi T, Terui K, Toki T, Watanabe T, Imaizumi T, Hama A, Iwamoto S, Hasegawa D, Ueda T, Yokosuka T, Tanaka S, Yanagisawa R, Koh K, Saito AM, Horibe K, Hayashi Y, Adachi S, Mizutani S, Taga T, Ito E, Watanabe K, Muramatsu H. Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome. Leukemia. 2021 May;35(5):1480-1484. doi: 10.1038/s41375-021-01171-y. Online ahead of print.PMID: 33654203
• Aoki T, Takahashi H, Tanaka S, Shiba N, Hasegawa D, Iwamoto S, Terui K, Moritake H, Nakayama H, Shimada A, Koh K, Goto H, Kosaka Y, Saito AM, Horibe K, Kinoshita A, Tawa A, Taga T, Adachi S, Tomizawa D. Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. Br J Haematol. 2021 Apr;193(1):176-180. doi: 10.1111/bjh.16656. Epub 2020 Apr 26.PMID: 32337716
• Ono S, Takeshita K, Kiridoshi Y, Kato M, Kamiya T, Hoshino A, Yanagimachi M, Arai K, Takeuchi I, Toita N, Imamura T, Sasahara Y, Sugita J, Hamamoto K, Takeuchi M, Saito S, Onuma M, Tsujimoto H, Yasui M, Taga T, Arakawa Y, Mitani Y, Yamamoto N, Imai K, Suda W, Hattori M, Ohara O, Morio T, Honda K, Kanegane H.Hematopoietic cell transplantation rescues inflammatory bowel disease and dysbiosis of gut microbiota in XIAP deficiency. J Allergy Clin Immunol Pract. 2021 Oct;9(10):3767-3780. doi: 10.1016/j.jaip.2021.05.045. Epub 2021 Jul 8.PMID: 34246792
• Ohki K, Kiyokawa N, Watanabe S, Iwafuchi H, Nakazawa A, Ishiwata K, Ogata-Kawata H, Nakabayashi K, Okamura K, Tanaka F, Fukano R, Hata K, Mori T, Moriya Saito A, Hayashi Y, Taga T, Sekimizu M, Kobayashi R; Japan Children’s Cancer Study Group (JCCG). Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG). Br J Haematol. 2021 Aug;194(4):718-729. doi: 10.1111/bjh.17639. Epub 2021 Jul 13.PMID: 34258755
• Sasaki K, Tsujimoto S, Miyake M, Uchiyama Y, Ikeda J, Yoshitomi M, Shimosato Y, Tokumasu M, Matsuo H, Yoshida K, Ohki K, Kaburagi T, Yamato G, Hara Y, Takeuchi M, Kinoshita A, Tomizawa D, Taga T, Adachi S, Tawa A, Horibe K, Hayashi Y, Matsumoto N, Ito S, Shiba N. Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts. Br J Haematol. 2021 Jul;194(2):414-422. doi: 10.1111/bjh.17569. Epub 2021 Jun 13.PMID: 34120331
• Ohki K, Kiyokawa N, Watanabe S, Iwafuchi H, Nakazawa A, Ishiwata　K, Ogata KH, Nakabayashi K, Okamura K, Tanaka F, Fukano R, Hata K, Mori T, Saito AM, Hayashi Y, Taga T, Sekimizu M, Kobayashi R. Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG) Br J Haematol. 2021 Aug;194(4):718-729. doi: 10.1111/bjh.17639.

著書・総説

総説

• 多賀 崇、臨床血液学―診断と治療におけるパラダイムシフト2020－急性骨髄性白血病の微小残存病変、臨床血液．2020；61（4）：343-349
• 多賀 崇、急性白血病-最新の診断と治療-予後分類とMRD-　急性白血病におけるMRD、日本臨床．2020；78（3）：447-451
• 多賀 崇、リレー随筆：小児白血病、そして臨床研究の世界へ、小児科臨床. 2020; 73(6): 848-850
• 多賀 崇、RINKETSU Dictionary　ダウン症候群関連骨髄性白血病、臨床血液. 2021:62(5)；536
• 多賀 崇、ダウン症の骨髄性白血病治療、血液内科 2021:　83(2); 313-317

講演など

教育講演

シンポジウム

獲得研究費

2021年度

• 難治性疾患等政策研究事業　先天性骨髄不全症の診断基準・重症度分類・診療ガイドラインの確立に関する研究：CDAのデータ管理,診断基準の確立に関する研究
  分担研究者：多賀 崇
  （500,000円）
• AMED（革新的がん医療実用化研究事業）
  ダウン症合併骨髄性白血病に対する標準的治療法の確立
  研究担当者：多賀 崇
  （17,000,000円）
• AMED（革新的がん医療実用化研究事業）
  小児骨髄系腫瘍に対する標準的治療法の確立
  分担研究者：多賀 崇
  (260,000円)
• AMED（革新的がん医療実用化研究事業）
  t(8;21)およびinv(16)陽性AYA・若年成人急性骨髄性白血病に対する微小残存病変を指標とするゲムツズマブ・オゾガマイシン治療介入の有効性と安全性を評価する研究
  分担研究者：多賀 崇
  （130,000円）
• 国立がん研究センター研究開発費
  小児がんに対する個別化医療導入に関する研究：小児血液腫瘍分野における治療開発
  研究担当者（分担）：多賀 崇
  （5,000,000円）

2020年度

• 基盤研究（C）
  小児がん患者と経験者の生活を守る小児がん患者支援コーディネーターの養成
  研究担当者（分担）：多賀 崇
  （260,000円）
• （難治性疾患等政策研究事業（難治性疾患政策研究事業）先天性骨髄不全症の診断基準・重症度分類・診療ガイドラインの確立に関する研究：CDAのデータ管理,診断基準の確立
  分担研究者：多賀 崇
  （400,000円）
• AMED（革新的がん医療実用化研究事業）
  ダウン症合併骨髄性白血病に対する標準的治療法の確立
  研究担当者：多賀 崇
  （17,160,000円）
• AMED（革新的がん医療実用化研究事業）
  小児骨髄系腫瘍に対する標準的治療法の確立
  分担研究者：多賀 崇
  (260,000円)
• AMED（革新的がん医療実用化研究事業）
  t(8;21)およびinv(16)陽性AYA・若年成人急性骨髄性白血病に対する微小残存病変を指標とするゲムツズマブ・オゾガマイシン治療介入の有効性と安全性を評価する研究
  分担研究者：多賀 崇
  （260,000円）
• 国立がん研究センター研究開発費
  小児がんに対する個別化医療導入に関する研究：小児血液腫瘍分野における治療開発
  研究担当者（分担）：多賀 崇
  （3,000,000円）

2019年度

• 基盤研究(C)（一般）
  ダウン症候群合併骨髄性白血病の治療反応の多様性解明の研究
  研究代表者：多賀 崇
  （1,300,000円）
• (厚生労働科学研究費補助金)
  難治性疾患等政策研究事業（難治性疾患政策研究事業）先天性骨髄不全症の診断基準・重症度分類・診療ガイドラインの確立に関する研究：CDAのデータ管理,診断基準の確立
  分担研究者：多賀 崇
  （400,000円）
• AMED（革新的がん医療実用化研究事業）
  ダウン症合併骨髄性白血病に対する標準的治療法の確立
  研究担当者：多賀 崇
  （19,500,000円）
• AMED（革新的がん医療実用化研究事業）
  小児骨髄系腫瘍に対する標準的治療法の確立
  研究担当者：多賀 崇
  (260,000円)
• 国立がん研究センター研究開発費
  小児がんに対する個別化医療導入に関する研究：小児血液腫瘍分野における治療開発
  研究担当者（分担）：多賀 崇
  （3,000,000円）